Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T22:53:01.163Z.
Calculation as of: 2026-10-06T22:53:01.163Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 06d607300f47343d1cd5625897ab9451fc86a9e564f014de5145334d904f0225
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2015-05-11.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
EBITDA YIELD AVG TTM
N/A
EBITDA YIELD AVG 3Y
N/A
EBITDA YIELD AVG 5Y
N/A
EBITDA YIELD AVG 10Y
N/A
EBITDA YIELD AVG 15Y
N/A
EBITDA YIELD AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$12.78M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$13.20M
EBITDA Yield
N/A
TTM Avg
0.87%
3Y Avg
0.87%
5Y Avg
0.87%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tempest Therapeutics, Inc. (TPST) | $12.58M | N/A | N/A | N/A | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.48M | N/A | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.44M | N/A | N/A | N/A | N/A |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.78M | N/A | N/A | N/A | N/A |
| Lantern Pharma Inc. (LTRN)vs › | $12.17M | N/A | N/A | N/A | N/A |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.06M | N/A | N/A | N/A | N/A |
| Passage Bio, Inc. (PASG)vs › | $13.11M | N/A | N/A | N/A | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.20M | N/A | 0.87% | 0.87% | 0.87% |
| Biofrontera Inc. (BFRI)vs › | $11.93M | N/A | N/A | N/A | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.30M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA YIELD |
|---|---|
| 2015-05-11 | 0.00% |
| 2015-05-08 | 0.00% |
| 2015-05-07 | 0.00% |
| 2015-05-06 | 0.01% |
| 2015-05-05 | 0.01% |
| 2015-05-04 | 0.01% |
| 2015-05-01 | 0.01% |
| 2015-04-30 | 0.01% |
| 2015-04-29 | 0.00% |
| 2015-04-28 | 0.00% |
| 2015-04-27 | 0.00% |
| 2015-04-24 | 0.00% |
| 2015-04-23 | 0.00% |
| 2015-04-22 | 0.00% |
| 2015-04-21 | 0.00% |
| 2015-04-20 | 0.00% |
| 2015-04-17 | 0.00% |
| 2015-04-16 | 0.00% |
| 2015-04-15 | 0.00% |
| 2015-04-14 | 0.00% |
| 2015-04-13 | 0.00% |
| 2015-04-10 | 0.00% |
| 2015-04-09 | 0.00% |
| 2015-04-08 | 0.00% |
| 2015-04-07 | 0.00% |
| 2015-04-06 | 0.00% |
| 2015-04-02 | 0.00% |
| 2015-04-01 | 0.00% |
| 2015-03-31 | 0.00% |
| 2015-03-30 | 0.00% |
| 2015-03-27 | 0.00% |
| 2015-03-26 | 0.00% |
| 2015-03-25 | 0.00% |
| 2015-03-24 | 0.00% |
| 2015-03-23 | 0.00% |
| 2015-03-20 | 0.00% |
| 2015-03-19 | 0.00% |
| 2015-03-18 | 0.00% |
| 2015-03-17 | 0.00% |
